X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DISHMAN PHARMA AJANTA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 21.1 25.1 83.9% View Chart
P/BV x 9.1 3.3 272.1% View Chart
Dividend Yield % 0.7 0.7 99.2%  

Financials

 AJANTA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DISHMAN PHARMA
Mar-16
AJANTA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720374 459.4%   
Low Rs1,103129 855.7%   
Sales per share (Unadj.) Rs194.6197.8 98.4%  
Earnings per share (Unadj.) Rs45.221.2 213.2%  
Cash flow per share (Unadj.) Rs50.334.7 144.9%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.8 71.3%  
Book value per share (Unadj.) Rs132.0179.9 73.4%  
Shares outstanding (eoy) m88.7780.69 110.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.3 570.1%   
Avg P/E ratio x31.211.9 263.0%  
P/CF ratio (eoy) x28.17.2 387.2%  
Price / Book Value ratio x10.71.4 764.2%  
Dividend payout %17.79.4 187.6%   
Avg Mkt Cap Rs m125,29920,306 617.1%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,5705,355 48.0%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m17,27515,961 108.2%  
Other income Rs m166265 62.7%   
Total revenues Rs m17,44216,226 107.5%   
Gross profit Rs m5,8074,103 141.5%  
Depreciation Rs m4511,091 41.3%   
Interest Rs m49944 5.2%   
Profit before tax Rs m5,4742,334 234.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460624 234.1%   
Profit after tax Rs m4,0141,711 234.6%  
Gross profit margin %33.625.7 130.8%  
Effective tax rate %26.726.7 99.8%   
Net profit margin %23.210.7 216.7%  
BALANCE SHEET DATA
Current assets Rs m7,63911,018 69.3%   
Current liabilities Rs m2,7159,517 28.5%   
Net working cap to sales %28.59.4 303.1%  
Current ratio x2.81.2 243.1%  
Inventory Days Days43110 39.1%  
Debtors Days Days7935 225.8%  
Net fixed assets Rs m6,91416,304 42.4%   
Share capital Rs m177161 109.6%   
"Free" reserves Rs m11,44212,907 88.6%   
Net worth Rs m11,72114,516 80.7%   
Long term debt Rs m1494,189 3.5%   
Total assets Rs m14,81429,805 49.7%  
Interest coverage x112.93.5 3,253.9%   
Debt to equity ratio x00.3 4.4%  
Sales to assets ratio x1.20.5 217.8%   
Return on assets %27.48.9 307.8%  
Return on equity %34.211.8 290.5%  
Return on capital %46.517.5 265.4%  
Exports to sales %55.124.8 222.5%   
Imports to sales %6.03.7 160.8%   
Exports (fob) Rs m9,5273,956 240.8%   
Imports (cif) Rs m1,038596 174.0%   
Fx inflow Rs m10,4224,952 210.5%   
Fx outflow Rs m1,678697 240.8%   
Net fx Rs m8,7444,255 205.5%   
CASH FLOW
From Operations Rs m3,2642,786 117.1%  
From Investments Rs m-2,093-1,529 136.9%  
From Financial Activity Rs m-1,186-941 126.0%  
Net Cashflow Rs m-15316 -4.7%  

Share Holding

Indian Promoters % 73.8 61.4 120.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 12.7 59.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 22.1 76.9%  
Shareholders   20,968 46,261 45.3%  
Pledged promoter(s) holding % 4.4 35.8 12.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS